Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T deLeon

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Plos One|March 21, 2020
Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutationsThomas T DeLeon, Daniel R Almquist, Benjamin R Kipp, et al.
Digestive Diseases and Sciences|November 13, 2021
FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic AlterationsPedro Luiz Serrano Uson Junior, Thomas T DeLeon, James M Bogenberger, et al.
Journal of the National Cancer Institute|April 11, 2023
Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinomaKristen Spencer, Leontios Pappas, Islam Baiev, et al.
JCO Precision Oncology|August 10, 2023
The Cholangiocarcinoma in the Young (CITY) Study: Tumor Biology, Treatment Patterns, and Survival Outcomes in Adolescent Young Adults With CholangiocarcinomaLeontios Pappas, Islam Baiev, Stephanie Reyes, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Plos One|March 21, 2020
Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutationsThomas T DeLeon, Daniel R Almquist, Benjamin R Kipp, et al.
Digestive Diseases and Sciences|November 13, 2021
FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic AlterationsPedro Luiz Serrano Uson Junior, Thomas T DeLeon, James M Bogenberger, et al.
Journal of the National Cancer Institute|April 11, 2023
Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinomaKristen Spencer, Leontios Pappas, Islam Baiev, et al.
JCO Precision Oncology|August 10, 2023
The Cholangiocarcinoma in the Young (CITY) Study: Tumor Biology, Treatment Patterns, and Survival Outcomes in Adolescent Young Adults With CholangiocarcinomaLeontios Pappas, Islam Baiev, Stephanie Reyes, et al.
Pageof 2